(vianews) - shares of erytech pharma (cac 40: eryp.pa) jumped by a staggering 16.66% to €0.90 at 10:55 est on monday, after four successive sessions in a row of losses. cac 40 is jumping 1.1% to €7,266.61, following the last session's downward trend. this seems, at the moment, an all-around bullish trend trading session today.
erytech pharma's last close was €0.77, 65.86% under its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-3.99.
volume
today's last reported volume for erytech pharma is 176344 which is 72.1% below its average volume of 632106.
more news about erytech pharma (eryp.pa).